Literature DB >> 1919169

Effects of tumor-necrosis-factor-activated neutrophils on tumor cell survival.

H Shau1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1919169     DOI: 10.1007/bf02918159

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


× No keyword cloud information.
  53 in total

1.  Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system.

Authors:  A el-Hag; R A Clark
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

Review 2.  Resistance of tumor cells to tumor necrosis factor.

Authors:  H M Shepard; G D Lewis
Journal:  J Clin Immunol       Date:  1988-09       Impact factor: 8.317

3.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

4.  Regulation of human lymphocyte-mediated natural killer (NK) cell activity. I. Inhibition in vitro by peripheral blood granulocytes.

Authors:  H D Kay; D L Smith
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

5.  Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor.

Authors:  J R Gamble; J M Harlan; S J Klebanoff; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

6.  Phase I study of recombinant tumor necrosis factor in cancer patients.

Authors:  M Blick; S A Sherwin; M Rosenblum; J Gutterman
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

7.  Recombinant tumor necrosis factor causes activation of human granulocytes.

Authors:  J W Larrick; D Graham; K Toy; L S Lin; G Senyk; B M Fendly
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

8.  Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.

Authors:  A Asher; J J Mulé; C M Reichert; E Shiloni; S A Rosenberg
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

9.  Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor.

Authors:  R J Zimmerman; A Chan; S A Leadon
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

10.  Studies on the relationship of human natural killer and lymphokine-activated killer cells with lysosomal staining and analysis of surface marker phenotypes.

Authors:  H Shau; D Gray; M S Mitchell
Journal:  Cell Immunol       Date:  1988-08       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.